Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
NCT04700124
recruiting
Enrollment Count
784
ESTIMATED
Enrollment Rate
High
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
NCT03924856
active not recruiting
Enrollment Count
907
ACTUAL
Enrollment Rate
High
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Sun Yat-sen University
Urinary Bladder Neoplasms
NCT05975307
not yet recruiting
Enrollment Count
64
ESTIMATED
Enrollment Rate
Low
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
NCT03520491
recruiting
Enrollment Count
45
ESTIMATED
Enrollment Rate
Low
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)
Samsung Medical Center
Urinary Bladder Neoplasms
NCT05453682
recruiting
Enrollment Count
53
ESTIMATED
Enrollment Rate
Low
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Yonsei University
Urinary Bladder Neoplasms
NCT04686149
not yet recruiting
Enrollment Count
39
ESTIMATED
Enrollment Rate
High
Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Urinary Bladder Neoplasms
NCT04966975
not yet recruiting
Enrollment Count
60
ESTIMATED
Enrollment Rate
Medium
Multicentric Prospective T1 Urinary Bladder Cancer Registry
Medical University of Vienna
Urinary Bladder Neoplasms
NCT05792033
recruiting
Enrollment Count
700
ESTIMATED
Enrollment Rate
High
Neoadjuvant Chemotherapy in Non Muscle Invasive T1b Bladder Cancer
Assiut University
Urinary Bladder Neoplasms
NCT04245618
not yet recruiting
Enrollment Count
50
ESTIMATED
Enrollment Rate
High
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
NCT03924895
recruiting
Enrollment Count
857
ESTIMATED
Enrollment Rate
High
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Pfizer
Urinary Bladder Neoplasms
NCT04165317
active not recruiting
Enrollment Count
1070
ACTUAL
Enrollment Rate
High